Amano T, Kumini K, Nakashima K, Uchibayashi T, Hisazumi H
Department of Urology, School of Medicine, Kanazawa University, Japan.
J Urol. 1990 Aug;144(2 Pt 1):370-4. doi: 10.1016/s0022-5347(17)39463-6.
A combined therapy of hyperthermia (43.5 C) and tumor necrosis factor (10(3) and 10(4) units) for the treatment of experimental bladder carcinoma KK-47 in athymic mice was studied. Briefly, mice were injected subcutaneously with 10(7) disaggregated cells. When the tumors were 250 mm3 in size, tumor necrosis factor was administered, either intravenously or by intratumor injection. Intravenous injection was 10(3) to 10(4) units tumor necrosis factor in the tail vein and intratumor was 10(3) to 10(4) units injected directly into the center of the tumor. Immediately following injection, the tumor bearing leg was placed in a 43.5 C water bath for 20 minutes. Tumor size was monitored once a week for seven weeks and the animals were divided into control, hyperthermia alone, tumor necrosis factor alone and combined therapy. Results of the study showed no significant difference in 10(3) units of tumor necrosis factor intravenously versus control but a significant regression in hyperthermia alone. Anti-tumor effects significantly increased in hyperthermia plus 10(3) units tumor necrosis factor versus hyperthermia alone. Similar results were seen with 10(4) units tumor necrosis factor intravenously though in the combination group of hyperthermia and tumor necrosis factor, eight mice of eight died one to three days following treatment. In those receiving intratumor injections, there was no difference between tumor necrosis factor or control. Tumor necrosis factor with hyperthermia had the approximate same characteristics as hyperthermia alone and therefore there was no synergistic finding. These results reflect on the suggestion that the combination therapy of hyperthermia and systemic administration of the proper dosage of tumor necrosis factor may produce synergistic anti-cancer effects in bladder cancer patients.
研究了热疗(43.5℃)与肿瘤坏死因子(10³和10⁴单位)联合治疗无胸腺小鼠实验性膀胱癌KK - 47的效果。简要来说,给小鼠皮下注射10⁷个分散细胞。当肿瘤大小达到250立方毫米时,通过静脉注射或瘤内注射给予肿瘤坏死因子。静脉注射是在尾静脉注射10³至10⁴单位肿瘤坏死因子,瘤内注射是将10³至10⁴单位直接注射到肿瘤中心。注射后立即将荷瘤腿置于43.5℃水浴中20分钟。每周监测一次肿瘤大小,持续七周,并将动物分为对照组、单纯热疗组、单纯肿瘤坏死因子组和联合治疗组。研究结果显示,静脉注射10³单位肿瘤坏死因子与对照组相比无显著差异,但单纯热疗组肿瘤有显著消退。热疗加10³单位肿瘤坏死因子组的抗肿瘤效果比单纯热疗组显著增强。静脉注射10⁴单位肿瘤坏死因子时也观察到类似结果,不过在热疗和肿瘤坏死因子联合治疗组中,八只小鼠中有八只在治疗后一至三天死亡。在接受瘤内注射的小鼠中,肿瘤坏死因子组与对照组之间没有差异。肿瘤坏死因子与热疗联合的情况与单纯热疗具有大致相同的特征,因此未发现协同作用。这些结果表明,热疗与适当剂量的肿瘤坏死因子全身给药联合治疗可能对膀胱癌患者产生协同抗癌作用。